ITeos Therapeutics Doses First Patient in Phase 3 Trial of Belrestotug With Dostarlimab; Triggers $35 Million GSK Payment

iTeos Therapeutics (ITOS) said Monday it has dosed the first patient in its phase 3 trial of belrestotug with dostarlimab, triggering a $35 million development milestone payment from its belrestotug p

MT NewswiresJul 8 07:54 ET

Express News | Iteos Announces First Patient Dosed in Galaxies Lung-301 Phase 3 Study, Earning $35 Million in Milestones From GSK

ReutersJul 8 07:00 ET

Sector Update: Health Care Stocks Advance in Afternoon Trading

Health care stocks were rising Friday afternoon, with the NYSE Health Care Index adding 0.5% and the Health Care Select Sector SPDR Fund (XLV) up 0.4%. The iShares Biotechnology ETF (IBB) gained 0.4%.

MT NewswiresJul 5 14:04 ET

ITeos, Arcus Shares Drop After Genentech's Lung Cancer Study Misses Endpoints

iTeos Therapeutics (ITOS) and Arcus Biosciences (RCUS) shares fell in early Friday trading after Roche Group's Genentech said its phase 2/3 non-small cell lung cancer study failed to meet its primary

MT NewswiresJul 5 10:08 ET

Express News | Shares of Compugen Down 3%, Iteos Therapeutics Down 6.1%, and Arcus Biosciences Down 3.8%

ReutersJul 5 09:35 ET

Express News | Anti-Tigit Drugmakers Fall as Roche's Lung Cancer Drug Fails Trial

ReutersJul 5 09:34 ET